Taiwan
· Delayed Price · Currency is TWD MARX Biotech Statistics
Total Valuation
MARX Biotech has a market cap or net worth of TWD 3.68 billion. The enterprise value is 3.59 billion.
| Market Cap | 3.68B |
| Enterprise Value | 3.59B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MARX Biotech has 498.06 million shares outstanding. The number of shares has increased by 33.97% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 498.06M |
| Shares Change (YoY) | +33.97% |
| Shares Change (QoQ) | +4.63% |
| Owned by Insiders (%) | 18.72% |
| Owned by Institutions (%) | n/a |
| Float | 325.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.09 |
| PB Ratio | 14.93 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -53.76 |
| EV / Sales | 8.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -50.94 |
Financial Position
The company has a current ratio of 2.13, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.13 |
| Quick Ratio | 1.41 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.11 |
| Interest Coverage | -207.44 |
Financial Efficiency
Return on equity (ROE) is -33.66% and return on invested capital (ROIC) is -19.72%.
| Return on Equity (ROE) | -33.66% |
| Return on Assets (ROA) | -13.43% |
| Return on Capital (ROIC) | -19.72% |
| Revenue Per Employee | 5.55M |
| Profits Per Employee | -833,687 |
| Employee Count | 80 |
| Asset Turnover | 1.45 |
| Inventory Turnover | 2.00 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 8.68 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 36.00 |
| Average Volume (20 Days) | 896,914 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MARX Biotech had revenue of TWD 444.16 million and -66.70 million in losses. Loss per share was -0.14.
| Revenue | 444.16M |
| Gross Profit | 327.72M |
| Operating Income | -65.76M |
| Pretax Income | -68.89M |
| Net Income | -66.70M |
| EBITDA | -58.96M |
| EBIT | -65.76M |
| Loss Per Share | -0.14 |
Balance Sheet
The company has 97.96 million in cash and 7.74 million in debt, giving a net cash position of 90.22 million or 0.18 per share.
| Cash & Cash Equivalents | 97.96M |
| Total Debt | 7.74M |
| Net Cash | 90.22M |
| Net Cash Per Share | 0.18 |
| Equity (Book Value) | 246.24M |
| Book Value Per Share | 0.49 |
| Working Capital | 185.71M |
Cash Flow
In the last 12 months, operating cash flow was -67.25 million and capital expenditures -3.14 million, giving a free cash flow of -70.38 million.
| Operating Cash Flow | -67.25M |
| Capital Expenditures | -3.14M |
| Free Cash Flow | -70.38M |
| FCF Per Share | -0.14 |
Margins
Gross margin is 73.78%, with operating and profit margins of -14.80% and -15.02%.
| Gross Margin | 73.78% |
| Operating Margin | -14.80% |
| Pretax Margin | -15.51% |
| Profit Margin | -15.02% |
| EBITDA Margin | -13.27% |
| EBIT Margin | -14.80% |
| FCF Margin | -15.85% |
Dividends & Yields
MARX Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.97% |
| Shareholder Yield | -33.97% |
| Earnings Yield | -1.86% |
| FCF Yield | -1.91% |
Stock Splits
The last stock split was on July 11, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Jul 11, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
MARX Biotech has an Altman Z-Score of 12.09.
| Altman Z-Score | 12.09 |
| Piotroski F-Score | n/a |